PRIME MEDICINE
🇮🇳India
- Country
- 🇮🇳India
- Ownership
- Public
- Established
- 2019-01-01
- Employees
- 234
- Market Cap
- $517.3M
- Website
- http://www.primemedicine.com
A Study of the Safety and Efficacy of Prime Editing (PM359) in Participants with P47phox Autosomal Recessive Chronic Granulomatous Disease (CGD )
Phase 1
Recruiting
- Conditions
- Chronic Granulomatous DiseaseGranulomatous Disease, Chronic
- Interventions
- Biological: PM359
- First Posted Date
- 2024-08-19
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Prime Medicine, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT06559176
- Locations
- 🇺🇸
University of California Los Angeles Medical Center, Los Angeles, California, United States
🇺🇸NIH Clinical Center, Bethesda, Maryland, United States
🇨🇦CHU - Sainte Justine Hospital, Montréal, Quebec, Canada
© Copyright 2025. All Rights Reserved by MedPath